Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 29.06 billion. The enterprise value is 15.73 billion.

Market Cap	29.06B
Enterprise Value	15.73B

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+59.45%
Shares Change (QoQ)	-3.50%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	143.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.82
EV / Sales	0.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.25

Financial Position

The company has a current ratio of 0.93

Current Ratio	0.93
Quick Ratio	0.89
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.37
Interest Coverage	-17.46

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-10.76%
Return on Capital (ROIC)	n/a
Revenue Per Employee	11.23M
Profits Per Employee	-3.62M
Employee Count	1,543
Asset Turnover	0.53
Inventory Turnover	19.68

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +153.33% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+153.33%
50-Day Moving Average	177.04
200-Day Moving Average	207.61
Relative Strength Index (RSI)	50.66
Average Volume (20 Days)	2,939

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.90

Income Statement

In the last 12 months, Novavax had revenue of MXN 17.33 billion and -5.58 billion in losses. Loss per share was -38.98.

Revenue	17.33B
Gross Profit	2.26B
Operating Income	-5.68B
Pretax Income	-5.48B
Net Income	-5.58B
EBITDA	-4.76B
EBIT	-5.68B
Loss Per Share	-38.98

Full Income Statement

Balance Sheet

The company has 17.81 billion in cash and 5.14 billion in debt, giving a net cash position of 12.68 billion.

Cash & Cash Equivalents	17.81B
Total Debt	5.14B
Net Cash	12.68B
Net Cash Per Share	n/a
Equity (Book Value)	-10.31B
Book Value Per Share	-64.37
Working Capital	-1.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.78 billion and capital expenditures -390.95 million, giving a free cash flow of -2.17 billion.

Operating Cash Flow	-1.78B
Capital Expenditures	-390.95M
Free Cash Flow	-2.17B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 13.04%, with operating and profit margins of -32.76% and -32.18%.

Gross Margin	13.04%
Operating Margin	-32.76%
Pretax Margin	-31.60%
Profit Margin	-32.18%
EBITDA Margin	-27.48%
EBIT Margin	-32.76%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-59.45%
Shareholder Yield	-59.45%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -3.81. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.81
Piotroski F-Score	n/a